NEUROMETRIX, INC. (NASDAQ:NURO) Files An 8-K Results of Operations and Financial Condition
Item 2.02
NEUROMETRIX, INC. (NASDAQ:NURO) Files An 8-K Results of Operations and Financial Condition
On October 17, 2019, NeuroMetrix, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2019. The full text of the press release and the related attachment are furnished as Exhibit 99.1 hereto and incorporated herein by reference.
Exhibit No. Description
99.1 Press Release of NeuroMetrix, Inc. dated October 17, 2019.
NeuroMetrix, Inc. Exhibit
EX-99.1 2 a8k20191017prex991.htm EXHIBIT 99.1 Exhibit EXHIBIT 99.1NeuroMetrix Reports Q3 2019 Financial ResultsWOBURN,…
To view the full exhibit click
EX-99.1 2 a8k20191017prex991.htm EXHIBIT 99.1 Exhibit EXHIBIT 99.1NeuroMetrix Reports Q3 2019 Financial ResultsWOBURN,…
To view the full exhibit click
here
About NEUROMETRIX, INC. (NASDAQ:NURO)
NeuroMetrix, Inc. (NeuroMetrix) is a health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians manage chronic pain, nerve diseases and sleep disorders. The Company operates through the sale of medical equipment and consumables segment. Its products are sold in the United States and selected overseas markets. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The Company’s products consist of a medical device used in conjunction with a consumable electrode or biosensor. Its products include Quell, which is a wearable device for relief of chronic intractable pain; SENSUS, which is a prescription neuro-stimulation device; DPNCheck, which is a nerve conduction test that is used to evaluate systemic neuropathies, and ADVANCE System, which is a platform for the performance of nerve conduction studies.